The recent discovery of human-induced pluripotent stem cells (iPSC) has revolutionized the field of stem cells. iPSC have demonstrated that biological development is not an irreversible process and that mature adult somatic cells can be induced to become pluripotent. This breakthrough is projected to advance our current understanding of many disease 
generated human iPSC from human dermal fibroblasts using retroviral transduction with the same 4 transcription factors (8) . These iPSC have morphology, cell surface markers, and genes characteristics similar to human ESC, exhibiting unlimited replication potential without telomere shortening or karyotype changes.
The multilineage differentiation potential of iPSC has been confirmed both in vitro in embryoid bodies and in vivo based upon teratoma formation upon injection into severe combined immunodeficient (SCID) mice.
Other groups reproduced the "stemness" or induced pluripotency of somatic cells using the same or slightly different transcription factors, demonstrating the robustness of this technique and revolutionizing the field of stem cell biology (9) (10) (11) .
Since the ability to generate iPSC in culture from adult human skin fibroblasts has been established (8, 9) , this pluripotent state has been induced in a variety of human cells including keratinocytes (12) , T-lymphocytes (13) , peripheral mononuclear blood cells (14) , cord blood (15) , placenta (16) , neural stem cells (17) , adipose tissue (18) , and renal epithelial cells present in urine samples (19) (16, (22) (23) (24) (25) . Currently, the first human trials of iPSC-derived cells, aimed at establishing the safety of these cells, are enrolling patients with age-related macular degeneration in Japan (26) .
Beyond the potential for regenerative or transplantation therapies, iPSC offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby providing novel cell-based biological models that enable better understanding of disease pathogenesis and drug discovery (27) . From 2008 to 2015, more than 70 human iPSC-based disease models have been published in an exponential fashion (28) Currently, it is widely thought that the pluripotent stem cell derivatives from either ESC or iPSC are still premature for clinical therapy because of the tumorigenic potential. Active research is ongoing using highly purified monolayer populations of differentiated iCM and methods to remove the undifferentiated iPSC (38). Through these efforts, the generation of >90% pure populations of iCM is increasingly routine in laboratories worldwide (39).
Using a single transcription factor (Oct3/4), Pasha et al were able to generate iPSC from mouse skeletal myoblasts that endogenously express 3 of the Yamanaka factors (40). They were also able to isolate cardiac progenitors from 5-day beating embryoid bodies.
In this experiment, iPSC-derived cardiac progenitor cells showed sustained engraftment and gap junction formation upon transplantation into the infarcted murine heart (40). Another group reported significantly restored cardiac function in post-MI ventricular remodeling after intramyocardial injection of fetal-liver kinase 1-positive iPSC-derived cardiac Youssef et al. ). In most of these studies, the mechanism underlying the positive results was postulated to be a "paracrine effect"
(22,32,58). The shortcoming of the paracrine effect hypothesis is that it is difficult to measure this
Youssef et al. (63) and failing hearts (64) showed that the heart may possess significant regenerative capacity, contradicting the old dogma of the heart as a terminally differentiated organ. These Pluripotency can be induced from a variety of human cells (12) (13) (14) (15) (16) (17) (18) (19) , and the best cell of origin for induction of pluripotency for cardiac application is not known yet. Several studies have suggested that after induction of pluripotency, somatic cells retain some characteristics of their past identity, the socalled epigenetic memory (78) . Although this epigenetic memory can be seen as a sign of incomplete programming, it can be used to facilitate differentiation toward the desired cell type more efficiently (27) .
Another technical issue is the low efficiency of the reprogramming process, which ranges from as much however, applies to almost all autologous cell therapies requiring in vitro expansion.
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FUTURE DIRECTIONS FOR CARDIOVASCULAR REGENERATION
Despite the limited innate ability of the injured myocardium and vasculature to regenerate, the implementation of iCM and iEC holds promise for Youssef et al. 
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Cardiovascular Application of iPSC advances in bioengineering such as the disease-ona-chip technology will take these models from an individual cell to the tissue level (114) . With such advances, modeling genetic mitochondrial cardiomyopathy on a chip has become a reality (115) . iPSC-derived disease models not only include genetic abnormalities but also structural heart diseases such as the hypoplastic left heart syndrome (116) . A full list of iPSC-derived cardiovascular disease models is shown in Table 1 .
For drug testing, iPSC-derived disease models can serve as an additional in vitro arm to augment phase II and phase III clinical trials for dose optimization, These novel models and experimental constructs will perfuse drug solutions on iPSC-derivatives, including hepatic, renal, pulmonary, and cardiac cells in series or parallel, to simulate the multisystem interactions within the body and to assess important toxicities and/or side effects.
SUMMARY AND CONCLUSIONS
iPSC represent a promising tool for cardiovascular regeneration, disease modeling, and drug discovery.
Despite some encouraging results in pre-clinical studies using iCM for cardiac regeneration, longterm engraftment remains challenging and the long-term results are unclear. It is possible that these issues may be ameliorated with the use of alternative
